Reversible methamphetamine-induced cardiomyopathy mimicking arrhythmogenic right ventricular cardiomyopathy with ventricular tachycardia

Aidan (Jia Sheng) Yu, MBBS,* Matthew Rowe, MBBS,† Paul Martin, MBChB,* Arun Dahiya, MBBS*

From the *Royal Brisbane & Women’s Hospital, Herston, Australia, and †Princess Alexandra Hospital, Woolloongabba, Australia.

Introduction
Among numerous etiologies of ventricular arrhythmias, arrhythmogenic right ventricular cardiomyopathy (ARVC) and methamphetamine-induced cardiomyopathy (MAC) are 2 of the rarer causes of ventricular arrhythmias.1 ARVC is a disease that is characterized by fibro-fatty replacement of the myocardium.1 Although it was originally described as a right ventricular (RV) disease, left ventricular (LV) and biventricular involvement are also possible in patients with ARVC.1 On the other hand, MAC is a separate clinical entity that is rare and under-recognized.2

We report the first known case of reversible MAC mimicking ARVC with ventricular tachycardia (VT).

Case report
A 44-year-old white man presented with recurrent episodes of syncope on exertion. A nonsustained monomorphic VT, which was captured on his electrocardiogram (ECG) (Figure 1A), self-terminated but was associated with presyncope. His past medical history was significant for regular methamphetamine use, but he had no known medical conditions or family history of cardiac disorders. This patient did not have any cardiovascular risk factors. On average, he smoked 100 mg of methamphetamine and ingested 100 mg of liquid methamphetamine each week. He reported he last used intravenous methamphetamine a year ago. He also reported a 20-pack-year smoking history and drank 6 standard drinks per week. He denied using other illicit drugs.

A transthoracic echocardiogram was performed, which revealed impaired LV systolic function with an LV ejection fraction (LVEF) of 39% (Simpson biplane). There was also mild concentric LV hypertrophy with global hypokinesis. Both left and right ventricles were borderline dilated. The right ventricular outflow tract (RVOT) parasternal long-axis RV dimension was 47 mm, RVOT parasternal short-axis RV dimension 49 mm, and RV longitudinal myocardial velocity 7.6 cm/s. A coronary angiogram was performed and showed normal coronary arteries.

Further evaluation for ARVC included cardiac magnetic resonance imaging (MRI) with gadolinium enhancement. This showed multiple RV regional wall motion abnormalities with dyssynchronous contraction in the RVOT and apical RV free wall (Figure 2A and B, Supplementary Video 1). The sub-tricuspid RV free wall also appeared dyskinetic and there were areas of sub-segmental dyskinesis in the RVOT. The RV end-diastolic volume index was 87 mL/m² and RV ejection fraction (RVEF) was measured at 36%. There was also global hypokinesis of the left ventricle with a measured LVEF of 35%. There was no obvious gadolinium enhancement of both ventricles to suggest fibrotic or fat changes.

KEY TEACHING POINTS
• Methamphetamine-induced cardiomyopathy (MAC) can mimic arrhythmogenic right ventricular cardiomyopathy (ARVC) with ventricular tachycardia. It is important to establish the correct diagnosis, as the disease process and long-term management differ significantly.
• The revised Task Force criteria are crucial in diagnosing ARVC but must be interpreted in the appropriate clinical context.
• Cardiac magnetic resonance imaging can be a useful tool in defining myocardial injury, predicting reversibility, and monitoring the progress of MAC.
A signal-averaged ECG (SAECG) was also conducted. This was positive, with a filtered QRS duration of 118 ms (normal <114 ms), root mean square voltage of terminal 40 ms of 38 μV (normal >20 μV), and duration of low-amplitude signal of 33 ms (normal <38 ms).

Under the Revised Task Force Criteria for ARVC, this patient met 1 major criterion (dyssynchronous RV contraction and RVEF <40%) and 2 minor criteria (nonsustained VT of left bundle branch block morphology with inferior axis, late potentials by SAECG), which meets the criteria for a definite diagnosis for ARVC.¹

Electrophysiology study revealed no inducible sustained VT despite isoprenaline provocation. Voltage mapping of the right ventricle was performed using a 3-dimensional mapping system with bidirectional FlexAbility catheter (EnSite NavX; Abbott, Chicago, IL) and did not find any low-voltage areas suggestive of fibrosis, which can be seen in ARVC.

Beta-blocker and angiotensin-converting enzyme inhibitors were initiated. The patient was monitored with telemetry on the ward and had been free of ventricular arrhythmia since admission. Nine days into his admission, his telemetry captured multiple episodes of monomorphic VT (Figure 1B) of similar morphology seen at presentation. On further questioning, he admitted to ingesting methamphetamine brought in by a friend. A decision was made not to insert an implantable cardioverter-defibrillator (ICD) in this admission given the clear temporal relationship of methamphetamine use and ventricular arrhythmia, freedom from arrhythmia on beta-blocker while abstaining from methamphetamine, and the risk of device infection given previous intravenous drug use. He was discharged on bisoprolol and perindopril. Drug and alcohol services were engaged to provide ongoing community detoxification therapy.

At the patient’s 5-month follow-up appointment, he reported significantly reduced methamphetamine use. His repeat cardiac MRI showed resolution of previously seen RV segmental regional wall motion abnormalities and normalization of RV systolic function with an RVEF of 50% (Figure 2C and D, Supplementary Video 2). In addition, there was no focal LV regional wall motion abnormality and LVEF had improved to 55%. His outpatient 24-hour Holter monitor showed no VT. He demonstrated complete recovery of his cardiac function and the diagnosis of reversible cardiomyopathy owing to methamphetamine was made. We have continued follow-up for 18 months at the time of writing, and his course has been complicated by relapses in drug use and medication noncompliance, leading to further RVOT VT and syncope.

Figure 1  A: A 12-lead electrocardiogram demonstrating monomorphic ventricular tachycardia of right ventricular outflow tract morphology. B: Telemetry captured nonsustained monomorphic ventricular tachycardia of similar morphology following ingestion of methamphetamine on the ward.
Discussion

This case demonstrates the importance of establishing the correct underlying pathology of ventricular arrhythmia and the value of a thorough history including potential precipitants. Although our patient admitted to illicit drug use, many patients, for various reasons, may not. Methamphetamine use is common in Western countries such as Australia and, as such, should be directly inquired about.

Despite similar initial treatment approach to ventricular arrhythmias, the clinical course and long-term management for ARVC and MAC differ significantly. The placement of an ICD in a potentially reversible condition such as MAC would not only be unnecessary, but would also have exposed the patient to the risk of complications such as infection and inappropriate shocks.

Methamphetamine is a sympathomimetic agent that can result in stress-induced cardiomyopathy through inhibition of presynaptic catecholamine uptake and promotion of noradrenaline release. There are no pathognomonic imaging findings for MAC, but it can manifest as either acute LV impairment or chronic dysfunction or resemble Takotsubo syndrome. Past studies have shown that dilated cardiomyopathy is the most common type of cardiomyopathy associated with methamphetamine use. Dilatation of the ventricles was also evident in our case. In comparison to non-methamphetamine users, patients with MAC are more prone to having increased LV end-diastolic volume, end-systolic volume, left atrial volume, and RV dimensions. In addition, methamphetamine users are known to have increased LV mass. This may be related to the increased sympathetic drive resulting in tachycardia and vasoconstriction that contribute to ventricular hypertrophy. Global LV systolic dysfunction with reduced LVEF is common in these patients.

Theories on the mechanism of MAC include coronary vasospasm and increased reactive oxygen species with resulting LV dilatation and systolic dysfunction. Methamphetamine use stimulates a hyperadrenergic state with resultant stress-induced cardiomyopathy through inhibition of presynaptic catecholamine uptake and promotion of noradrenaline release. Autopsy studies in MAC have revealed contraction band necrosis, normally found in catecholamine toxicity such as cocaine and pheochromocytoma-induced

Figure 2  A: Cardiac magnetic resonance imaging demonstrating dyskinesia of right ventricular outflow tract (RVOT). B: Resolution of RVOT dyskinesia at 5-month follow-up. C: Cardiac magnetic resonance imaging demonstrating dyskinetic basal right ventricular (RV) free wall. D: Resolution of RV free wall dyskinesia at 5-month follow-up.
cardiomyopathy. In addition, methamphetamine also activates Ca/calmodulin-dependent protein kinase, which causes myocardial hypertrophy and fibrosis. A range of ECG abnormalities have been described in methamphetamine users. These abnormalities include prolonged QT interval, tachyarrhythmias, right axis deviation, LV hypertrophy, P pulmonale pattern, inferior Q waves, and lateral T-wave inversion. The most common ECG abnormality in this population is prolonged QTc, followed by nonspecific ST-T changes, sinus tachycardia, and sinus bradycardia. Notably, prolonged QTc increases the risk of arrhythmia, particularly polymorphic VT. In contrast, our patient’s ECG demonstrated monomorphic VT following ingestion of methamphetamine. Monomorphic VT following methamphetamine use has been reported in 1 case report; however, this particular patient had entirely normal echocardiographic and cardiac MRI findings. A “reverse Takotsubo” (RT) pattern has also been described in methamphetamine users where there is hypokinesia or akinesia of the basal mid segments with apical preservation. The majority of these patients were female with a background of shorter duration of methamphetamine use. The RT pattern observed may be due to the distribution of adrenergic receptors. There is increased sympathetic innervation and fewer β2 receptors in the basal region compared to the apical myocardium. Methamphetamine use increases not only concentrations of adrenaline, but also dopamine and noradrenaline. The β2-adrenoceptors can suppress a high level of adrenaline but not noradrenaline. Therefore, the basal myocardium will be most affected, thus producing these wall motion abnormalities.

Reports of cardiac MRI findings on methamphetamine users are scarce. Findings that have been described are mid-wall delayed gadolinium enhancement, LV dilatation, and systolic dysfunction in methamphetamine users. In contrast, cardiac MRI findings in ARVC include regional RV wall motion abnormality (akinesia, dyskinesia, or dys-synchronous RV contraction), increased RV end-diasolic volume, depressed RVEF, intramyocardial fat, late gadolinium enhancement, and focal wall thinning. These abnormalities (RV dysynchronous contraction and decreased RVEF) found in our patient resolved with reduced methamphetamine use. Sporadic case reports have described reversibility of cardiomyopathy upon cessation of methamphetamine use. This may be owing to withdrawal of catecholamine surge and decreased adrenergic stress on the heart, similar to what is observed in stress-induced cardiomyopathy and pheochromocytoma-induced cardiomyopathy. In our case, despite poor compliance with beta-blockers and angiotensin-converting enzyme inhibitor therapy, this patient’s cardiomyopathy resolved with reduction of methamphetamine use. The necessary dose and duration of methamphetamine usage required to develop cardiomyopathy is still unclear, as both acute and chronic forms of MAC have been reported. This may be owing to variations in individual response and tolerance to the drug. In theory, the absence of macroscopic fibrosis as shown by negative gadolinium enhancement is usually indicative of no permanent myocardial insult. This may be more indicative of a favorable prognosis. This correlated with our patient, whose cardiac MRI did not demonstrate gadolinium enhancement and who made an excellent recovery. In addition, echocardiographic features that favor early recovery include smaller left ventricular or left atrial size. ARVC is a genetically determined disease characterized by fibro-fatty replacement of the myocardium. Although it predominantly affects the right ventricle, biventricular and left-dominant forms are now recognized. The disease is a result of desmosomal dysfunction when exposed to mechanical stress, culminating in myocyte separation and death. Inflammation ensues as the body attempts to repair the damaged myocytes, which produces fibro-fatty replacement of the myocardium. Both autosomal dominant and recessive patterns have been described, with the dominant pattern being more common. The genes involved include plakoglobin, desmoplakin, plakophilin-2, desmoglein-2, desmocollin-2, TMEM43, RyR2, and TGF-beta-3. The goal of treatment is to prevent sudden cardiac death and to slow disease progression. High-intensity and endurance sports are not recommended owing to the known risk of ventricular arrhythmias and disease progression. Beta-blockers and ICD play an important role in preventing sudden cardiac death. In addition, antiarrhythmic drugs such as sotalol can be used in patients with frequent ICD shocks, and rarely, cardiac transplantation is considered. Several disorders mimicking ARVC have been described. When these conditions involve the RV it is not uncommon for the task force criteria to be met. The well-known mimics are sarcoidosis and myocarditis, which may cause RV scarring and can be difficult to differentiate. Other conditions that could mimic RV pressure/volume overload on imaging include ostium secundum atrial septal defect, sinus venosus defect, severe tricuspid regurgitation, and pulmonary hypertension. However, the clinical history and associated findings of these other conditions are usually sufficient to separate them from ARVC. SAEKG is used to identify delayed and fragmented ventricular myocardial depolarization, which could provide the substrate for re-entrant arrhythmias. Kamath and colleagues found that using either 1 or 2 of the criteria (filtered QRS duration, root mean square voltage of terminal 40 ms, low-amplitude signal) increased the sensitivity of diagnosing ARVC while maintaining high specificity. However, it is important to note that an abnormal SAEKG is only a marker of RV cardiomyopathic process and not exclusive to ARVC. The abnormal SAEKG in this case is interesting, as our patient did not have scar or slow conduction on MRI or electrophysiology study. We believe that the dysynchrony in RV mechanical activation altered the QRS in much the same
way LV dyssynchrony does in heart failure, resulting in a positive SAECG without true late potentials.

The original task force criteria proposed in 1994 to aid the diagnosis of ARVC were revised in 2010 to improve the sensitivity of diagnosing early disease and familial disease.1 This patient fulfilled 1 major and 2 minor criteria, which would have classified him as having a definite diagnosis of ARVC. However, it was evident that our patient’s diagnosis was more consistent with MAC rather than ARVC given the history of methamphetamine use and normalization of cardiac function on follow-up.

**Conclusion**

To the best of our knowledge, this is the first reported case of reversible MAC mimicking ARVC with VT. Patients with a history of methamphetamine use who present with syncope and ventricular arrhythmias warrant a work-up for MAC. Establishing the correct diagnosis will aid long-term management and avoid unnecessary therapies. LV and RV dysfunction associated with methamphetamine use can be reversible with reduced drug use.

**Appendix**

**Supplementary data**

Supplementary data associated with this article can be found in the online version at https://doi.org/10.1016/j.hrcr.2019.11.007.

**References**